L&C Bio

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • No specific quantified financial risks or derivative exposures disclosed in the risk management section for FY2025
• • No new derivative contracts, new debt covenants, or additional financial risks indicated in FY2025 report

Management Discussion & Analysis

• • Revenue KRW 85.5B (+19% YoY), operating profit KRW 4.4B (+14%), net loss KRW -138.2B due to non-cash derivative and valuation losses
• • Segment driver: consolidated gross profit KRW 45.4B (+27%) with 53% gross margin, improved product mix and new product expansion

Business Overview

• • Core revenue from human tissue grafts KRW 55.6B (80.05% of sales) and tissue-based medical devices KRW 10.1B (14.59%) in FY2025
• • MegaFill (skin powder type) production capacity increased to 249,600 units, 87.24% utilization in 2025 vs 124,800 units and 74.32% in 2024

What are the latest L&C Bio DART filings in 2026?

L&C Bio (KRX code 290650) has filed an annual report on March 24, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did L&C Bio file its most recent annual report?

L&C Bio filed its most recent annual report on March 24, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is L&C Bio's KRX stock code?

L&C Bio's KRX stock code is 290650. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 290650 to look up all L&C Bio disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does L&C Bio file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for L&C Bio.

Where can I find L&C Bio financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from L&C Bio annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.